Recent Publications 2021-2023

  1. A sulphated glycosaminoglycan extract from Placopecten magellanicusinhibits the Alzheimer’s disease β-Site amyloid precursor protein cleaving enzyme 1 (BACE-1). Mycroft -West C.J., Devlin A.J., Cooper L.C., Guimon S.E., Procter P., Miller, G.J., Guerrini M., Fernig D.G., Yates E.A., Lima M.A., Skidmore M.A. Carbohydr. Res. 2023, 525, 108747.
  2. Analysis of Heparin Samples by Attenuated Total Reflectance Fourier-Transform Infrared Spectroscopy in the Solid State. Devlin A.J., Mycroft-West C.J., Turnbull J.E., Lima M.A., Guerrini M., Yates E.A., Skidmore M.A. ACS central 2023,
  3. Quantitative 2D 1H, 13C HSQC NMR spectroscopy for the determination of chondroitin sulfate and dermatan sulfate content in danaparoid sodium. Gardini C., Boccardi G., Guerrini M., Kellenbach E., Lunenburg M., van der Meer JY., Naggi A., Urso E. Thromb Haemost 2023 DOI
  1. Blended heparin: a new perspective to guarantee the supply of a life-saving drug? Guerrini M. Clinical and Applied Thrombosis/Hemostasis 2023, 29, 1-2.

  1. NMR spectroscopy and chemometric models to detect a specific non-porcine ruminant contaminant in pharmaceutical heparin. Colombo E., Mauri L., Marinozzi M., Rudd T.R., Yates E.A., Ballabio D., Guerrini M. 2022 J. Pharm. Biomed. Anal. 214, 114724
  2. Initial contact between SARS-CoV-2 spike S1 protein and cell surface glycans involves multiple binding modes. Parafioriti M., Ni M., Petitou M., Mycroft-West M.J., Rudd T.R., Gandhi N.S., Ferro V., Turnbull J.E., Lima M.A., Skidmore M.A., Fernig D.G., Yates E.A., Bisio A., Guerrini M., and Elli S. ChemRχiv. 2022, DOI: 26434/chemrxiv-2022-21brb
  3. Pentosan polysulfate inhibits attachment and infection by SARS-CoV-2 in vitro: insights into structural requirements for binding. Bertini S., Alekseeva A., Elli S., Pagani I., Zanzoni S., Eisele G., Krishnan R., Maag K.P., Reiter C., Lenhart D., Gruber R., Yates E.A., Vicenzi E., Naggi A., Bisio A., Guerrini M. 2022 Thromb. Haemost. 122, 867-880.

  1. Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain Schuurs ZP, Hammond E, Elli S, Rudd TR, Mycroft-West CJ, Lima MA, Skidmore MA, Karlsson R, Chen YH, Bagdonaite I, Yang Z, Ahmed YA, Richard DJ, Turnbull J, Ferro V, Coombe DR, Gandhi NS. Comput Struct Biotechnol J. 2021;19:2806-2818.
  1. Combined Analytical Approaches to Standardize and Characterize Biomaterials Formulations: Application to Chitosan-Gelatin Cross-Linked Hydrogels Magli, S. Rossi, L. Cosentino, C. Bertini S., Nicotra F., and Russo, L. Biomolecules 2021, 11, 683.
  1. Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a 3 clinical trial. Holubovska, H., Bojkova, D., Elli, S., Bechtel, M., Boltz, D., Muzzio, M., Peng, X., Sala, F., Cosentino, C., Mironenko, A., Milde, J., Lebed, Y., Stammer, H., Goy, A., Guerrini, M., Mueller, L., Cinatl, J., R Margitich, V., Velthuis, AJW. (2021) medRxiv